Dätwyler (DAE) CMD 2025 summary

Strategic direction and transformation

• Launched the 'Forward Now' transformation program to proactively drive change, targeting CHF 52 million cumulative effects and at least CHF 24 million annual improvement by end of 2027.

• Strategy sharpened to focus on high-value, system-critical components in healthcare and industrial sectors, targeting niches with high entry barriers and stable margins.

• Six growth drivers include unlocking production capacity, improving product mix, strengthening co-development, increasing share of wallet, accelerating innovation commercialization, and targeted acquisitions.

• Local-for-local production and regional sourcing enhance resilience, flexibility, and sustainability, with growth centers shifting to the Americas and Asia.

• Selective approach aligns with megatrends like demographics, health, technology, geopolitical shifts, and sustainability.

Business and market positioning

• Organized into healthcare and industrial divisions; healthcare generates over 40% of revenue and more than half of EBIT, with industrial contributing nearly 60% of sales but less than half of EBIT.

• Healthcare and Food & Beverage represent 60% of revenue, providing stability and exposure to long-term growth markets.

• Business model leverages material expertise, solution design, and product industrialization, supported by proprietary standards and global reach.

• High entry barriers include significant investment, regulatory compliance, and long-term customer partnerships.

• Nearly two-thirds of revenue comes from low-cyclicality markets, providing stability.

Innovation and technology pipeline

• Innovation pipeline managed through a stage-gate process, focusing on product, process, and material innovation in high-value applications.

• Next-generation technologies include electroactive and magnetically active polymers, soft dry electrodes, and hydrogen solutions.

• SoftPulse® for body signal monitoring and soft sensors/actuators for energy-efficient, miniaturized applications are being commercialized.

• New products like NeoFlex and soft pulse electrodes are entering serial production, with significant sales expected in the next 12–15 months.

• Advanced simulation and digital twin technologies are used to optimize product design and manufacturing.